Accéder au contenu
Merck

Novel non-benzimidazole chk2 kinase inhibitors.

Bioorganic & medicinal chemistry letters (2006-01-31)
Kelly J McClure, Liming Huang, Kristen L Arienti, Frank U Axe, Anders Brunmark, Jon Blevitt, J Guy Breitenbucher
RÉSUMÉ

In a recent paper, [Arienti, K. L.; Brunmark, A.; Axe, F. U.; McClure, K. M.; Lee, A.; Blevitt, J.; Neff, D. K.; Huang, L.; Crawford, S.; Chennagiri, R. P.; Karlsson, L.; Brietenbucher, J. G. J. Med. Chem.2005, 48, 1873], we described the discovery of a class of benzimidazole chk2 kinase inhibitors, exemplified by compound 1, which had radio-protective effects in human T-cells subjected to ionizing radiation. Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
4-Phenoxybenzaldehyde, 98%